We’ll be at ISPOR EU 2025 in Glasgow

ISPOR is the world’s premier scientific and educational event for health economics and outcomes research (HEOR). Each year, it brings together leaders, decision-makers, and innovators who are shaping the future of healthcare. This November 9-12, we are excited to join ISPOR EU 2025 in Glasgow to share our expertise, showcase our research, and engage with the global HEOR community.

Where to Find Us

We will be at booth #211. Stop by and connect with our experts! 

The poster titles you might want to visit

Don’t miss out on the poster sessions throughout the duration of the conference for a chance to view some of our recent work across a range of topics.

1. Out of sight, out of mind? A simulation study assessing the use of Quantitative Bias Analysis for Outcome Misclassification in Single-Arm Trials with External Control Comparisons (Leahy T, Barbier S, Turner A) (Wed 9:00am–11:30am)
2. Influence of NICE Real-World Evidence Framework on HTA Submissions: Sensitivity Analyses in Real-World External Control Arm Studies (Leahy T, Keenan C, Robertshaw E, Barbier S, McStravick M, Turner A) (Tue 10:30am–1:30pm) Top 5% Abstract finalist 
3. Machine Learning Applications in Treatment Pattern Analysis Using Real-World Data: A Scoping Review (Jabłońska K, Czubin A, Ludwikowska M, Barbier S, Majewska R) (Tue 4:00pm–7:00pm)
4. Comprehensive Landscape Assessment of Real-World Databases for HEOR Studies in the Asia-Pacific Region: A growing opportunity (Mazumder D, Majewska R, Barbier S, Patel R, Ghosh A) (Mon 4:00pm–7:00pm)
5. Real-world hospital stays description and cost analysis of Immune Checkpoint Inhibitors (ICIs) using national PMSI data in France (Virely N, Tournier C, Leboucher C, Barbier S, Sivignon M) (Tue 4:00pm–7:00pm)
6. National implementation of the EU HTA Regulation: Progress and Strategic Developments Across Member States (Koćwin A, Dimassi M, Remuzat C, Brogaard N [Novo Nordisk], Francois C) (Tue 4:00pm–7:00pm)
7. Acceptance of Artificial Intelligence in Evidence and Dossier Development by Global HTA Agencies (Skowron R, Remuzat C, Barbier S, Francois C) (Mon 10:30am–1:30pm)
8. From French Early Access to Regular Reimbursement: How Do Prices Shift Post-HTA? (Dimassi M, Grioui N, Remuzat C, Hanna E, Francois C) (Mon 4:00pm–7:00pm)
9. Win Ratio in the Presence of Censored Data: Can Probabilistic Variants Improve Robustness? (Nikodem M, Janik J, Barbier S, Kochmański M, Pierzchała P) (Tue 4:00pm–7:00pm)
10. Scoping the Future: Using NICE Scopes to Inform PICO Prediction for EU Joint Clinical Assessment (Cork D, Bannister C, Koćwin A, McEntee-Richardson L, Pannett S, Jaros P, Remuzat C) (Tue 4:00pm–7:00pm)
11. Uncertainty about how to translate JCA into national HTA submissions (EU-4 and Poland): a systematic comparison from an industry perspective (Kuchenbecker U, Dimassi M, Kuciara A, Francois C, Pannett S, Nikodem M) (Wed 9:00am–11:30am)
12. Balancing Rigour and Feasibility of Real-World Data Demands in Germany within the EU HTA context – How Fit for Purpose is the Routine Practice Data Collection (Anwendungsbegleitende Datenerhebung, AbD)? (Kuchenbecker U, Majewska R, Kuciara A, Francois C, Pannett S) (Mon 10:30am–1:30pm)
13. Improving the Transferability of Global RCT Data to Inform Cost-Effectiveness Models in Japan: A Structured Framework for C2H Submissions (Turner A, Onishi Y, Nomoto M, Leboucher C, Francois C) (Tue 10:30am–1:30pm)
14. Organizational and environmental impact of switching from intravenous to subcutaneous Immune Checkpoint Inhibitors (ICIs) in France: A Real-World analysis using PMSI data (Virely N, Sivignon M, Sellami R, Tournier C, Chouaid C [CHI Créteil, France]) (Wed 9:00am–11:30am)
15. Advancing Preference Elicitation Techniques for Rare Diseases and Limited Sample Populations (King W, Toledo V, Hill S, Oluboyede Y) (Tue 1:45pm–2:45pm, live podium presentation)
16. Spain Levelling Up: A Comparison of Spain’s New National Health Economic Evaluation Guideline With Those of England, France, Germany, Italy, Portugal, Sweden, Ireland, Canada, Australia, and Japan (Naz A, Jaros P, Francois C, Onishi Y, Crossan C, Pannett S) (Wed 9:00am–11:30am)
17. Budget Impact Models in CEESP opinions: A decade of insights (Doghri O, Boukhris Y, Sivignon M, Supiot R, Sellami R, Virely N) (Mon 10:30am–1:30pm)
18. Incidence of Treatment-Related Adverse Events from Immune Checkpoint Inhibitors: A Meta-Analysis of Randomized Clinical Trials (Bilthare S, Ranjan S, Phalswal A, Kolli N, Vidyasagar K, Ameen R, Potluri R) (Tue 10:30am–1:30pm)
19. Inpatient cost of managing adverse event (AE) associated with immune checkpoint inhibitors (ICI) approved for advanced or metastatic cancers in the UK (Gandhi J, Ranjan S, Mukherjee A, Sambhare S, Ameen R, Potluri R) (Tue 4:00pm–7:00pm)

See our full suite of Value, Pricing & Access services